Carbohydrate intake is associated with time spent in the euglycemic range in patients with type 1 diabetes. by Ayano-Takahara, Shiho et al.
Title Carbohydrate intake is associated with time spent in theeuglycemic range in patients with type 1 diabetes.
Author(s)
Ayano-Takahara, Shiho; Ikeda, Kaori; Fujimoto, Shimpei;
A ai, Kanae; Oguri, Yasuo; Harashima, Shin-Ichi; Tsuji,
Hidemi; Shide, Kenichiro; Inagaki, Nobuya




© 2015 The Authors. Journal of Diabetes Investigation
published by Asian Association of the Study of Diabetes
(AASD) and Wiley Publishing Asia Pty Ltd; This is an open
access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits
use and distribution in any medium, provided the original work
is properly cited, the use is non-commercial and no




Carbohydrate intake is associated with time
spent in the euglycemic range in patients with
type 1 diabetes
Shiho Ayano-Takahara1, Kaori Ikeda1, Shimpei Fujimoto1,2, Kanae Asai3, Yasuo Oguri1, Shin-ichi Harashima1, Hidemi Tsuji3,
Kenichiro Shide3, Nobuya Inagaki1*
1Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, 3Department of Metabolism and Clinical Nutrition, Kyoto University Hospital,
Kyoto, and 2Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kochi, Japan
Keywords
Dietary carbohydrates, Glycemic







J Diabetes Investig 2015; 6: 678–686
doi: 10.1111/jdi.12360
ABSTRACT
Aims/Introduction: Greater glycemic variability and lack of predictability are important
issues for patients with type 1 diabetes. Dietary factors are one of the contributors to this
variability, but how closely diet is linked to glycemic fluctuation on a daily basis has not
been investigated. We examined the association between carbohydrate intake and glyce-
mic excursion in outpatients.
Materials and Methods: A total of 33 patients with type 1 diabetes were included in
the analyses (age 44.5 – 14.7 years, diabetes duration 15.1 – 8.3 years, 64% female, 30%
using insulin pump, glycated hemoglobin 8.1 – 1.3%). Time spent in euglycemia (70–
180 mg/dL), hyperglycemia (>180 mg/dL) and hypoglycemia (<70 mg/dL) of consecutive
48-h periods of continuous glucose monitoring data were collected together with simulta-
neous records of dietary intake, insulin dose and physical activity. Correlation analyses and
multiple regression analyses were used to evaluate the contribution of carbohydrate intake
to time spent in the target glycemic range.
Results: In multiple regression analyses, carbohydrate intake (b = 0.53, P = 0.001), basal
insulin dose per kg per day (b = -0.31, P = 0.034) and diabetes duration (b = 0.30,
P = 0.042) were independent predictors of time spent in euglycemia. Carbohydrate intake
(b = -0.51, P = 0.001) and insulin pump use (b = -0.34, P = 0.024) were independent
predictors of time spent in hyperglycemia. Insulin pump use (b = 0.52, P < 0.001) and
bolus insulin dose per kg per day (b = 0.46, P = 0.001) were independent predictors of
time spent in hypoglycemia.
Conclusions: Carbohydrate intake is associated with time spent in euglycemia in
patients with type 1 diabetes.
INTRODUCTION
Glucose variability is greater in type 1 diabetes patients than it
is in type 2 diabetes patients1–3, and the lack of predictability is
an important issue for type 1 diabetes patients and medical
staff in daily practice. Hypoglycemia is a complication of diabe-
tes treatment, and the frequency of severe hypoglycemia
increases when glucose is lowered. Larger glucose variability is
an additional risk factor for severe hypoglycemia4. Minimizing
glucose variability is therefore a plausible method for offsetting
the increased risk of hypoglycemia associated with tight glyce-
mic control. In contrast, type 1 diabetes patients with larger
glycemic variability retain higher glycated hemoglobin (HbA1c),
partly because of the difficulty in raising the insulin dosage or
physical activity due to fear of hypoglycemia4,5. Larger glucose
variability is associated with lower quality of life and lower
satisfaction of treatment6.
Clinical factors contributing to hypoglycemia and glycemic
variability have been investigated, and can be summarized asReceived 17 December 2014; revised 11 March 2015; accepted 31 March 2015
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dietary factors, physical activity, insulin regimen, monitoring
and pathophysiological conditions7–11. There have been few
studies of dietary factors; however, Maahs et al.9 reported a
positive association between carbohydrate intake and glucose
excursion during 1–4 h after the first meal of the day. In con-
trast, lower carbohydrate intake was associated with higher
HbA1c in the Diabetes Control and Complications Trial12. Fur-
ther research is required to learn the details of the association
of carbohydrate intake with glycemic control and glycemic vari-
ability on a daily basis.
Recently, continuous blood glucose monitoring (CGM) has
made it possible to monitor in detail glucose fluctuations in
daily life, and several indicators of intraday and interday glyce-
mic variability are now available4. Time spent in the glycemic
target range is a simple and absolute assessment of glycemic
control, reflecting both mean glucose level and glucose excur-
sions, and is sensitive to interventions13.
To investigate the overall influence of carbohydrate intake on
glycemic levels including both excursion and mean, we evalu-
ated the association between carbohydrate intake and time
spent in the target glycemic range by use of simultaneous die-
tary records and CGM in outpatient settings.
MATERIALS AND METHODS
Participants
The present cross-sectional study was carried out in Kyoto Uni-
versity Hospital between September 2011 and June 2012.
Patients aged 18 years or older who were diagnosed with
type 1 diabetes and were treated with basal–bolus therapy
(multiple daily injection [MDI] or continuous subcutaneous
insulin infusion [CSII]) were eligible for enrolment. Patients
were excluded if they had renal insufficiency (creatinine
≥1.5 mg/dL), liver failure, acute infection, psychological comor-
bidities or dementia, were pregnant, taking steroid medication,
or had received pancreas or islet transplantation. The study
protocol was approved by the Kyoto University Graduate
School and Faculty of Medicine Ethics Committee, and regis-
tered on University hospital Medical Information Network in
Japan (UMIN000005833). Written informed consent was
obtained from all participants.
Continuous Glucose Monitoring
All participants underwent a 72-h period of monitoring using
CGMS system GoldTM (Medtronic, Northridge, CA, USA).
The CGMS consists of a glucose oxidase-based sensor inserted
subcutaneously in an abdominal site and attached through
cable to a monitor. The monitor takes a reading every 10 s and
accumulates an average every 5 min for a total of 288 readings
per day. The participants were instructed to enter at least four
daily metered blood glucose measurements for calibration using
conventional glucose meters. They also kept records of insulin
dose and whether or not they carried out bolus adjustment by
carbohydrate-counting while wearing CGMS. The CGM data
could be read only after CGMS was removed. The data from
CGMS were downloaded using Minimed solutions CGMS
sensor 3.0C software. Further data management was carried
out using Microsoft Excel (Microsoft, Seattle, WA, USA).
According to Medtronic’s recommendation, the criteria that a
minimal correlation of 0.79 between the sensor glucose and
meter blood glucose values with a mean absolute error <28%
were used to determine the accuracy of the CGM data. Patients
whose CGM data deviated from these criteria were rescheduled
for wearing CGMS with a dietary record and physical activity
monitoring, and this second set of CGM data was used for the
analyses so long as the participants met the criteria. Glucose
values outside the range of 40–400 mg/dL were reported as
≤40 or ≥400 mg/dL. The first complete, consecutive 48-h per-
iod of valid CGM data beginning from midnight was analyzed
for each subject.
Glycemic Indices
Mean, standard deviation (SD) and time spent in euglycemia
(70–180 mg/dL), in hyperglycemia (>180 mg/dL) and in hypo-
glycemia (<70 mg/dL) were calculated from CGM data. Time
spent in the target range, expressed as a percentage in a total
48-h monitoring period, has been used in several studies for
assessing CGM data13,14. Time spent in euglycemia is a direct
index of appropriate glycemic control, and can reflect both
mean glucose and glucose excursions13.
Dietary Data
Patients recorded everything they ate for the 72-h period using
recording sheets and photographs of foods. We used two, com-
plete, consecutive whole-day records from 0.00 to 24.00 h. The
photographs were taken before and after consumption with a
ruler placed beside the foods as a scale for estimation of the
size of the portions. The validity of assessing diet using photo-
graphs as food intake records has been reported15. Registered
dietitians estimated the amount of foods from the recording
sheets and photographs, and calculated the weight of the ingre-
dients, carbohydrate, fat, protein, fiber and ethanol using com-
puter software program Excel Eiyo-kun version 4.5 (Kenpaku
Co. Ltd, Tokyo, Japan). Excel Eiyo-kun is a program designed
to calculate amounts of ingredients based on standard tables of
food composition in Japan16,17.
The composition of fat (% of energy) and protein (% of
energy) were calculated as follows: fat (g) 9 9/total energy
(kcal) and protein (g) 9 4/total energy (kcal), respectively. The
composition of carbohydrate (% of energy) was calculated as
100–(fat [% of energy] + protein [% of energy]). These calcula-
tions were used to determine fat intake, protein intake and car-
bohydrate intake in the following analyses.
We defined snacking after dinner as a small intake of food
and/or beverage with energy after dinner excepting those for
treating hypoglycemia, and ‘Snacking after dinner’ was coded 1
for any episode of snacking after dinner during the 2 days, and
0 otherwise. ‘Late dinner’ was coded 1 for any dinner after
21.00 h during the 2 days, and 0 otherwise.
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Physical Activity Level
We measured the physical activity using Lifecoder PLUS
(Suzuken, Nagoya, Japan) during CGM. This method involves
uniaxial accelerometry and has been validated for assessment of
physical activity-related energy expenditure18. The patients
attach it onto a belt when they awake and take it off before
they go to sleep. The device samples acceleration at 32 Hz and
assesses values ranging from 0.06 to 1.94 g (1.00 g is equal to
the acceleration of free fall). A maximum pulse over 4 s is
taken for the acceleration value, and activity is categorized into
11 levels. The activity levels are subsequently converted to cal-
culate energy expenditure due to various activities (kcal). Total
energy expenditure (TEE) is calculated from the sum of the
basal metabolic rate, thermic effect of food (=1/10[TEE]) and
energy expenditure as a result of activity. Basal metabolic rate
is calculated from bodyweight, height, sex and age using a stan-
dard Japanese formula19. The physical activity level is calculated
as follows: TEE (kcal)/basal metabolic rate (kcal). The average
of two consecutive days that coincided with the 2 days of
CGM data was used.
Coefficient of Variation of R-R Intervals
We measured the coefficient of variation of R-R intervals
(CVR-R) for assessment of autonomic neuropathy20,21. The
R-R interval was measured by electrocardiography for 1 min in
the supine position after at least 3 min rest using CardioStar
FCP-7301 (Fukuda Denshi, Tokyo, Japan). The CVR-R was
calculated by dividing the SD by the mean (M):
CV (%) = (SD/M) 9 100.
Laboratory Measurements
Glycemic control was assessed by HbA1c and glycated albu-
min (GA). In all patients, HbA1c and GA levels were evalu-
ated within 2 weeks after CGM was initiated. HbA1c was
measured by reversed-phase cation exchange chromatography,
using ADAMSTMA1c HA-8180 (Arkray, Kyoto, Japan). The
CV of within-run reproducibility and between-run reproduc-
ibility were reported to be within 1%. The value for HbA1c
(%) was estimated as a National Glycohemoglobin Standardi-
zation Program equivalent value (%) calculated by the for-
mula HbA1c (%) = 1.02 9 HbA1c Japan Diabetes Society
(%) + 0.25%, measured by the previous Japanese standard
substance and measurement methods and HbA1c (National
Glycohemoglobin Standardization Program)22. GA was mea-
sured by the enzymatic method, using JCA-BM8000 series
(JOEL, Tokyo, Japan). The CV of within-run reproducibility
is 0.8–1.0%, and that of between-run reproducibility is 1.2%.
Serum C-peptide was measured by Chemiluminescent
Enzyme Immunoassay, LUMIPULSE Presto C-peptide (Fuji
Rebio, Tokyo, Japan). The CV of within-run reproducibility
is 1.96–2.97%, and that of between-run reproducibility is
1.06–2.60%. The measurement range of serum C-peptide is
0.02–30 ng/mL. For C-peptide measurement, blood samples
were centrifuged immediately at 1,880 g for 5 min. Serum
was stored at -80°C and measured within 1 month after
collection.
Glucagon Stimulation Test
A glucagon stimulation test was carried out after overnight 8-h
fast. Tests were rescheduled if the participant had a capillary
glucose value <70 mg/dL. Serum C-peptide was measured before
and 6 min after the intravenous injection of 1 mg glucagon23.
Hypoglycemia
The participants were asked about their experience of hypogly-
cemia over the past year on the day of starting CGM, and a
Clarke score (0 = no hypoglycemia; ≥4 = hypoglycemia
unawareness) was calculated24.
Statistical Analyses
Analysis was carried out using STATA 11.2 (StataCorp LP,
College Station, TX, USA). Pearson’s product–moment correla-
tion coefficient was used to evaluate the relationship between
glycemic indices and clinical variables including dietary intake.
We then carried out multiple regression analyses for the associ-
ation between carbohydrate intake and glycemic indices adjust-
ing for other plausible determinants of glycemic indices. We
started from an empty model and added variables by signifi-
cance level <0.10 from the following candidate variables: age,
diabetes duration, body mass index (BMI), blood pressure, CSII
use, carbohydrate counting, fiber intake, snacking after dinner
episode, late dinner, insulin dose per kg per day, physical activ-
ity, CVR-R, lipid profiles, C-peptide and Clarke score in the
order of correlation coefficients with glycemic indices. Two-
sided P < 0.05 was considered statistically significant.
RESULTS
A total of 40 patients were recruited. Diet therapy for these
patients was based on advice from nutritionists. Of the 40
patients, one was found to be in a non-insulin-dependent-state
by serum C-peptide level25. In three patients, available CGM
data covered <48 h because of disconnection of the sensor or
calibration errors. One patient failed to measure CVR-R
because of atrial fibrillation. In another patient, there were
missing data because of problems with Lifecoder PLUS.
Another patient reported that he drank a large amount of alco-
hol (equivalent to more than 60 g of pure ethanol per day)
during monitoring because of a celebration party. These seven
patients were excluded from the analysis. None of the 33
remaining patients had clinical thyroid disease or were diag-
nosed with clinical ketosis.
The clinical characteristics and the measurements of the 33
patients analyzed are shown in Table 1. The mean age was
44.5 years, and most of them were not obese. Their C-peptide
levels were very low, and most were undetectable by highly
sensitive measurement. The distribution of intake of the three
macronutrients is shown in Figure 1. Carbohydrate intake cor-
related negatively with fat intake (r = -0.93, P < 0.001),
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although there was no significant correlation between carbohy-
drate intake and protein intake (r = -0.33, P = 0.061) or
between protein intake and fat intake (r = -0.04, P = 0.819).
Carbohydrate intake correlated positively with time spent in
euglycemia (r = 0.48, P = 0.005) and negatively with time
spent in hyperglycemia (r = -0.50, P = 0.003; Figure 2). Con-
versely, fat intake showed a negative correlation with time spent
in euglycemia (r = -0.44, P = 0.011) and a positive correlation
with time spent in hyperglycemia (r = 0.45, P = 0.009). Neither
carbohydrate intake nor fat intake correlated with time spent in
hypoglycemia (r = 0.20, P = 0.274 and r = -0.15, P = 0.400,
respectively). In addition, there was no significant relation-
ship between protein intake and time spent in euglycemia
(r = -0.17, P = 0.331), hyperglycemia (r = 0.23, P = 0.206) or
hypoglycemia (r = -0.14, P = 0.425).
The relationships between insulin dose and time spent in eu-
glycemia, hyperglycemia and hypoglycemia are shown in Fig-
ure 3. Total insulin dose per kg per day was positively
correlated with time spent in hypoglycemia (r = 0.47,
P = 0.006), but not with time spent in euglycemia (r = -0.15,
P = 0.409) or hyperglycemia (r = -0.15, P = 0.400). Basal insu-
lin dose per kg per day was not correlated with time spent in
euglycemia (r = -0.27, P = 0.135), hyperglycemia (r = 0.11,
P = 0.543) or hypoglycemia (r = 0.18, P = 0.303). Bolus insulin
dose per kg per day showed a positive correlation with time
spent in hypoglycemia (r = 0.48, P = 0.005), but not with time
spent in euglycemia (r = -0.03, P = 0.879) or hyperglycemia
(r = -0.25, P = 0.152).
We carried out multiple regression analyses for time spent in
euglycemia, hyperglycemia and hypoglycemia by forward selec-
tion from possible determinants considering simple correlation
coefficients. Independent variables for time spent in euglycemia
were selected from carbohydrate intake, basal insulin dose per
kg per day, diabetes duration, carbohydrate counting, fiber, tri-
glyceride, snacking after dinner, systolic blood pressure, physical
activity, CVR-R, BMI, CSII use, Clarke score, late dinner, age
Table 1 | Clinical characteristics of participants




BMI (kg/m2) 22.6 – 3.6
Diabetes duration (years) 15.1 – 8.3
Glucagon stimulated C-peptide
Detectable (≥0.02 ng/mL) 5 (15)
Undetectable 28 (85)




Carbohydrate counting 7 (21)
HbA1c (%) 8.1 – 1.3
Glycated albumin (%) 24.2 – 4.8
Lipid profile (n = 32)
LDL cholesterol (mg/dL) 97 – 24
HDL cholesterol (mg/dL) 74 – 18
Triglyceride (mg/dL) 86 – 56
Clarke score 1.6 – 1.3
CVR-R (%) 3.3 – 1.8
Physical activity 1.4 – 0.1
Blood pressure (mmHg)
Systolic 119 – 17
Diastolic 69 – 10
Total insulin dose/BW (U/kg) 0.69 – 0.21
Basal insulin dose/BW (U/kg) 0.29 – 0.10
Bolus insulin dose/BW (U/kg) 0.40 – 0.16
Glycemic indices measured
by CGM
Mean glucose (mg/dL) 160 – 48
SD (mg/dL) 64 – 16




(%) 52.8 – 19.6




(%) 35.3 – 24.0




(%) 11.9 – 14.0
Dietary data (average of
consecutive 2 days)




Energy (kcal) 1888 – 370




Fat intake (% of energy) 32.7 – 5.2
Table 1 (Continued)
Protein intake (% of energy) 15.1 – 2.0
Fiber (g) 12.6 – 3.6
Ethanol (g) 3.6 – 7.4
Late dinner (%) 7 (21)
Snacking after dinner (%) 15 (45)
Data are mean – standard deviation (SD) or n (%). BMI, body mass
index; BW, bodyweight; CGM, continuous glucose monitoring; CVR-R,
coefficient of variation of R-R intervals; Energy (including alcohol), total
energy intake including alcohol; Energy (including alcohol)/BW, total
energy intake including alcohol per bodyweight; Energy, total energy
intake excluding alcohol; Energy/BW, total energy intake excluding
alcohol per bodyweight; CSII, continuous subcutaneous insulin infusion;
HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; MDI, multiple daily injection.
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and glucagon-stimulated C-peptide in this order. Independent
variables for time spent in hyperglycemia were selected from
carbohydrate intake, CSII use, CVR-R, bolus insulin dose per
kg per day, age, carbohydrate counting, triglyceride, late dinner,
diabetes duration, snacking after dinner, glucagon-stimulated C-
peptide, BMI, fiber, systolic blood pressure, Clarke score and
physical activity, in this order. Independent variables for time
spent in hypoglycemia were selected from CSII use, bolus insu-
lin dose per kg per day, fiber, age, CVR-R, late dinner, carbo-
hydrate intake, BMI, physical activity, systolic blood pressure,
glucagon-stimulated C-peptide, snacking after dinner, diabetes
duration, triglyceride, carbohydrate counting and Clarke score,
in this order. We found that time spent in euglycemia was sig-
nificantly predicted by carbohydrate intake (b = 0.53,
P = 0.001), basal insulin dose per kg per day (b = -0.31,
P = 0.034) and diabetes duration (b = 0.30, P = 0.042), and
that time spent in hyperglycemia was predicted by carbohydrate
intake (b = -0.51, P = 0.001) and CSII use (b = -0.34,
P = 0.024; Table 2). Time spent in hypoglycemia was predicted
by CSII use (b = 0.52, P < 0.001) and bolus insulin dose per
kg per day (b = 0.46, P = 0.001).
We also analyzed the relationship between carbohydrate
intake and HbA1c or GA as indicators of average glycemia
over several months or weeks, respectively, and the relationship
between carbohydrate intake and glycemic indices calculated
from CGM data (Figure 4). There was no significant correla-
tion between carbohydrate intake and HbA1c (r = -0.14,
P = 0.438) or GA (r = -0.10, P = 0.590). In contrast, carbohy-
drate intake was significantly correlated with mean glucose cal-
culated from CGM data (r = -0.48, P = 0.005), SD (r = -0.37,
P = 0.033) calculated from CGM data and also time spent in
euglycemia (r = 0.48, P = 0.005) calculated from CGM data.
The strongest correlation was observed between HbA1c and
GA (r = 0.85, P < 0.001), and a relatively strong correlation
was observed between HbA1c and mean, between GA and
mean, and between mean and time spent in euglycemia
(r = 0.70, r = 0.65 and r = -0.69, respectively, all P < 0.001).
Time spent in euglycemia was moderately correlated with
HbA1c (r = -0.45, P = 0.008), but not with GA (r = -0.31,
P = 0.083).
DISCUSSION
The present study shows a clear association of carbohydrate
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Figure 1 | Distribution of intake of three macronutrients (% of energy) shown by two-way scatter plot. (a) Fat intake and carbohydrate intake.
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Figure 2 | (a) Correlations between carbohydrate intake and time
spent in euglycemia, hyperglycemia and hypoglycemia. (b) Correlations
between fat intake and time spent in euglycemia, hyperglycemia and
hypoglycemia.
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2-day period in a daily life setting of type 1 diabetes patients.
Notably, carbohydrate intake showed no association with
HbA1c or GA in the present study, showing that the associa-
tion of carbohydrate intake with euglycemia does not represent
a long-term interaction, but rather a short-term interaction, on
a daily basis.
The existing evidence of the association of carbohydrate
intake and glycemic control was estimated by food frequency
questionnaires, which assesses long-term nutritional exposure,
and HbA1c12,26, and there has been no association shown
between carbohydrate intake estimated by dietary records,
which assesses short-term nutritional exposure, and HbA1c27,28.
In the present study, carbohydrate intake was calculated by
dietary record during continuous monitoring of glucose levels.
Mean glucose level during monitoring is generally the best
index for correlating CGM with HbA1c, and showed an
association with carbohydrate intake, whereas HbA1c did not.
One reason could be that carbohydrate intake estimated by
dietary record is not a good measure of chronic exposure to
carbohydrate.
There was no trend found between carbohydrate intake and
time spent in hypoglycemia, but a significant inverse association
between carbohydrate intake and time spent in hyperglycemia
was observed. Carbohydrate intake in the participants of the
present study had a strong inverse correlation with fat intake,
and the contributions of carbohydrate intake and fat intake to
time in hyperglycemia and time in euglycemia were in the
opposite direction. The contributions of carbohydrate intake
were larger than those of fat intake. In contrast, protein intake
showed no association with time in any range. The present
results show that there is a relationship between increased car-
bohydrate intake or reduced fat intake and better short-term
glucose control, which is less time in hyperglycemia and more
time in euglycemia.
Insulin dose is also an important factor influencing glycemic
control in type 1 diabetes, and is reported to correlate with car-
bohydrate intake28–30. We included insulin dose in the multiple
regression models and observed an independent negative
association between basal insulin dose and time spent in











































































































0.2 0.4 0.6 0.8 1.0 1.2
0.2 0.4 0.6 0.8 1.0 1.2
0.2 0.4 0.6 0.8 1.0 1.2
0.1 0.2 0.3 0.4 0.5 0.6 0.2 0.4 0.6 0.8
0.1 0.2 0.3 0.4 0.5 0.6
0.1 0.2 0.3 0.4 0.5 0.6
0
0.2 0.4 0.6 0.80
0.2 0.4 0.6 0.80
Total insulin dose/BW (U/kg) Basal insulin dose/BW (U/kg) Bolus insulin dose/BW (U/kg)
(a) (b) (c)
Figure 3 | (a) Correlations between total insulin dose and time spent in euglycemia, hyperglycemia and hypoglycemia. (b) Correlations between
basal insulin dose and time spent in euglycemia, hyperglycemia and hypoglycemia. (c) Correlations between bolus insulin dose and time spent in
euglycemia, hyperglycemia and hypoglycemia. BW, bodyweight.
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bolus insulin dose and time spent in hypoglycemia, but no
association between insulin dose and time spent in hyperglyce-
mia. This might suggest that higher insulin dose per body-
weight is a risk for hypoglycemia. CSII use was another factor
associated with time spent in hypoglycemia, and also a factor
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Figure 4 | Relationship between carbohydrate intake and glycemic indices including glycated hemoglobin (HbA1c), glycated albumin (GA), mean
calculated from continuous blood glucose monitoring data, standard deviation calculated from continuous blood glucose monitoring data and
time spent in euglycemia calculated from continuous blood glucose monitoring data. SD, standard deviation.
Table 2 | Multivariate analyses for the determinants of time spent in target range








b P b P b P
Carbohydrate intake 0.53 0.001 -0.51 0.001 –
Basal insulin dose/BW -0.31 0.034 – –
Diabetes duration 0.30 0.042 – –
Carbohydrate counting 0.26 0.078 – –
CSII – -0.34 0.024 0.52 <0.001
Bolus insulin dose/BW – – 0.46 0.001
Late dinner – – 0.24 0.065
Adjusted R2 0.41 0.33 0.50
P <0.001 <0.001 <0.001
Variables were selected by the forward selection method, according to the significance level for addition of variables <0.10, from the following
candidate variables: carbohydrate intake, insulin dose per kg per day, diabetes duration, carbohydrate counting, continuous subcutaneous insulin
infusion (CSII) use, late dinner, fiber intake, lipid profiles, snacking after dinner episode, blood pressure, physical activity, coefficient of variation of R-R
intervals (CVR-R), Clarke score, body mass index, age and C-peptide. Basal insulin dose/BW, basal insulin dose per bodyweight; Bolus insulin dose/
BW, bolus insulin dose per bodyweight.
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contribute to reduce hyperglycemia, but might tend to increase
hypoglycemia, possibly more so under tight glycemic control.
Diabetes duration independently predicted euglycemia;
patients with longer duration spent a longer time in euglyce-
mia. Given that the CGM data in the present study were not
shown to the patients in real time, they were assumed to man-
age their glycemic level based on self-monitoring of blood glu-
cose and their experience. Patients might become skilled in
managing their glycemic fluctuation through their long experi-
ence. Carbohydrate counting was used by seven out of the 33
patients on the days that glucose was monitored. Carbohydrate
counting seemed to show a weak contribution to increased time
spent in euglycemia, but the contribution did not reach statisti-
cal significance. Among the other plausible predictors that we
included in the multiple regression models, fiber intake showed
a tendency to reduce hypoglycemia, but the contribution was
not significant when it was included in the model together with
CSII use and insulin dose. The C-peptide level was undetectable
by highly sensitive measurement in most patients in the present
study, even after glucagon stimulation, and a dummy variable
for C-peptide did not show a significant effect on time in target
range or other indicators of glycemic variability. Hypoglycemia-
associated autonomic failure can also increase hypoglycemia10.
However, in our data, CVR-R was not an independent predic-
tor of time spent in hypoglycemia. One reason for this could
be that the CVR-R used in this study was not under deep
breathing, but only the resting condition. Another limitation of
the present study was the relatively small sample size.
A strength of our study was that our carbohydrate intake
measurement did not reflect dietary history, but only the
amount of carbohydrate actually taken during the period that
the glucose level was continuously monitored. Time spent in a
target glycemic range that includes both mean glucose level and
glucose excursions on a daily basis is a suitable index for facili-
tation of glycemic control. We carried out additional analyses
using other indexes of glycemic variability, including mean
amplitude of glycemic excursions, coefficient of variation and
mean absolute glucose change, but there were no significant
findings.
Our data showed that carbohydrate intake ranged from 40%
to 60% of total energy intake, whereas the guideline recom-
mends that carbohydrate account for 50–60% of intake31.
Patients who consumed carbohydrate accounting for <50% of
total energy spent a shorter time in euglycemia and a longer
time in hyperglycemia. This could partly be due to the fact that
the insulin regimen was based mainly on carbohydrate intake,
which is not appropriate for a relatively high-fat diet. Although
fat content has been considered more important in controlling
bodyweight than in controlling glycemic level11, fat intake
delays the postprandial rise in blood glucose and makes peak
glucose occur later32. It might therefore contribute to the mis-
match of the insulin regimen and the glycemic level, and be a
cause of glycemic variability and unpredictability. Further
research is required to confirm these findings in experimental
settings focusing on postprandial glucose or in other groups of
patients whose intake is of a different composition of the three
major nutrients from that of the present study.
In conclusion, sufficient carbohydrate intake is clearly associ-
ated with favorable glycemic control in patients with type 1
diabetes using MDI or CSII.
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